Functional ageing in fibrotic interstitial lung disease: the impact of frailty on adverse health outcomes

Sabina A. Guler, Joanne M. Kwan, Janice M. Leung, Nasreen Khalil, Pearce G. Wilcox, Christopher J. Ryerson

Source: Eur Respir J, 55 (1) 1900647; 10.1183/13993003.00647-2019
Journal Issue: January
Disease area: Interstitial lung diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Sabina A. Guler, Joanne M. Kwan, Janice M. Leung, Nasreen Khalil, Pearce G. Wilcox, Christopher J. Ryerson. Functional ageing in fibrotic interstitial lung disease: the impact of frailty on adverse health outcomes. Eur Respir J, 55 (1) 1900647; 10.1183/13993003.00647-2019

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Can a better understanding of frailty improve the quality of life of patients with fibrotic interstitial lung diseases?
Source: Eur Respir J, 55 (1) 1902255; 10.1183/13993003.02255-2019
Year: 2020



COPD as a lung disease with heterogeneous systemic inflammatory consequences: clinical impact
Source: Research Seminar 2011 - Physical activity, nutritional status and systemic inflammation in COPD
Year: 2011


Quality of life and health status in interstitial lung diseases
Source: Annual Congress 2008 - COPD and miscellaneous
Year: 2008


Frequency and impact of interstitial lung disease on clinical state and mortality in systemic scleroderma
Source: Annual Congress 2012 - Diffuse parenchymal lung disease III
Year: 2012

Patient-reported quality of life in fibrotic interstitial lung disease: novel assessments of self-management ability and affect
Source: ERJ Open Res, 7 (1) 00011-2021; 10.1183/23120541.00011-2021
Year: 2021



The impact of aging on COPD, cardiovascular comorbidities and systemic inflammation
Source: International Congress 2019 – Cardiovascular comorbidities in COPD
Year: 2019

Health status and psychological assessments
Source: Annual Congress 2007 - PG6 - COPD: comprehensive clinical assessment and pharmacological and nonpharmacological therapy
Year: 2007



Neuropsychological status and health related quality of life in patients with chronic obstructive pulmonary disease
Source: Annual Congress 2007 - Clinical aspects of COPD II
Year: 2007


Predictors of quality of life in patients with interstitial lung disease
Source: Annual Congress 2009 - Sarcoidosis and profiles of other diffuse parenchymal lung disease
Year: 2009


Patients' perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases
Source: Eur Respir Rev, 27 (150) 180075; 10.1183/16000617.0075-2018
Year: 2018



Assessing cardiocirculatory compensation capacity in COPD: impact of disease severity.
Source: Virtual Congress 2020 – Respiratory diseases, hypoxia and cardiovascular function
Year: 2020

Increased self-management capacity leads to improved health outcomes for chronic lung disease patients
Source: Eur Respir J 2005; 26: Suppl. 49, 72s
Year: 2005

Community pulmonary rehabilitation for COPD: physical, psychological and quality of life improvements are independent of age and disease severity
Source: Eur Respir J 2007; 30: Suppl. 51, 93s
Year: 2007

Impact of social distancing during the COVID-19 pandemic on clinical outcomes of patients with interstitial lung disease
Source: Virtual Congress 2021 – Symptoms across respiratory diseases and impact of COVID-19
Year: 2021


Health-related quality of life and health status among patients with sarcoidosis, chronic obstructive pulmonary disease and interstitial lung disease
Source: International Congress 2018 – Granulomatous disorders: heterogeneous diseases with variable management
Year: 2018


Psychological predictors of health-related quality of life of interstitial lung disease patients.
Source: International Congress 2019 – The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment
Year: 2019

Exercise pulmonary haemodynamic response predicts outcomes in fibrotic lung disease
Source: Eur Respir J, 52 (3) 1801015; 10.1183/13993003.01015-2018
Year: 2018



Impact of preventing exacerbations on deterioration of health status in COPD
Source: Eur Respir J 2004; 23: 698-702
Year: 2004



Physical activity and clinical outcomes in patients with interstitial lung disease: how large is the impairment? – Preliminary results
Source: International Congress 2018 – Chronic respiratory disease : determinants of physical activity in patients
Year: 2018